Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9190372 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL3286142 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL6333157 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL4318209 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL9688834 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CA2CA1FPR2MAPK1 | |
| SCHEMBL9688830 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CA2CA1FPR2MAPK1 | |
| SCHEMBL28470269 | 0.78 | SLC7A5 (0.34) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL30533386 | 0.78 | SLC7A5 (0.34) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL15328461 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1CA2CA1GAA | |
| SCHEMBL33799 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042800-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) | 2026-02-12 | — | — | US | disclosed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | disclosed |
| US-20240228555-A9 | ANTIMICROBIAL PEPTIDOMIMETICS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-07-11 | — | — | US | disclosed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240132553-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20230295234-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| EP-4214220-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-4214221-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-115989237-A | Antimicrobial peptidomimetics | 斯派西斯公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115989236-A | Antimicrobial peptidomimetics | 斯派西斯公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022028737-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2022-02-10 | — | — | WO | disclosed |
| EP-0674652-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013695-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042800-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | CUTA, NGLY1, P4HB | SMN1; SMN2 4550/4885ALDH1A1 2742/4885CA2 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.